Predisposing Factors Associated With Chemotherapy Toxicity in Elderly Cancer Patients
NCT ID: NCT02317757
Last Updated: 2016-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2015-01-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer
NCT02517034
Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer
NCT02054741
Predicting Chemo Toxicity Using Geriatric Forms
NCT07163169
Improving Survivorship Care for Older Adults After Chemotherapy
NCT04405115
Perceptions of Side Effects of Cancer Chemoradiotherapy
NCT02978846
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cancer patients receiving chemotherapy
Patients who are older than 70 years old receiving chemotherapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* plan to receive first cycle of chemotherapy
* histologically or cytologically proved of cancer
Exclusion Criteria
* patients who received local chemotherapy
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mahidol University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Suthinee Ithimakin, MD
Role: PRINCIPAL_INVESTIGATOR
Mahidol University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of medical oncology, department of medicine Siriraj Hospital
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
559/2557(EC3)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.